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developed grade II to IV AGVHD, and 15 (20%) developed grades
III to IV AGVHD. In univariate analysis, advanced diseases, donor
and recipient age were signiﬁcant risk factors for developing
AGVHD. On the other hand, omitting day 11 MTX, Class I
and/or Class II HLA allele disparities, CMV seropositivity, or sex
mismatch were not identiﬁed as risk factors. The mean blood level
of tacrolimus during the ﬁrst three weeks were signiﬁcantly lower
in those who developed grade II to IV or III to IV AGVHD than
that of patients who did not (17.5 vs.15..8 vs.15.3 p  0.007, p 
0.015), and the level 15ng/ml during the third week was associ-
ated with the occurrence of moderate or severe AGVHD(p 
0.023). In multivariate analysis, only the mean concentration of
tacrolimus remained as a risk factor to develop moderate to severe
AGVHD. The incidence of nephrotoxicity (doubling of serum
creatinine) or hyperglycemia (BS 200mg/dl) did not signiﬁcantly
correlate with the mean blood level of tacrolimus until three weeks
after transplant; however, the incidence of those events signiﬁ-
cantly correlated with the tacrolimus blood level of a week before
the events thereafter (p  0.0001). These data suggest the impor-
tance of maintaining tacrolimus blood level above 15 ng/ml during
the ﬁrst three weeks after transplantation to optimize the efﬁcacy
while minimize its side effects.
117
THERAPEUTIC ANTIBODY MEDIATED DEPLETION OF ACTIVATED DEN-
DRITIC CELLS AND THE PREVENTION OF GRAFT VERSUS HOST DIS-
EASE
Wilson, J., Rice, A.M., Hart, D.N.J., Munster, D.J. Mater Medical
Research Institute, South Brisbane, Queensland, Australia.
Graft versus host disease (GVHD) is the most common compli-
cation of haemopoietic stem cell transplantation and contributes
signiﬁcantly to the morbidity and mortality of the procedure.
Current GVHD prevention targets donor T lymphocytes involved
in recipient tissue destruction. This strategy is associated with long
term immunosuppression, loss of the graft versus leukaemia effect
and graft failure. Dendritic cells (DCs) are a leucocyte population
of antigen presenting cells (APC) which, when activated, stimulate
the donor T lymphocyte attack in GVHD and as such, represent a
possible alternative therapeutic target. To investigate the effect of
DC depletion in GVHD, we used an established mouse-human
chimeric model of GVHD in which human T lymphocytes are
known to be effector cells. Brieﬂy, severe combined immunodeﬁ-
cient (SCID) mice were injected with whole or depleted human
PBMC, causing a GVHD-like syndrome that was measured by
mouse survival and human cell engraftment. Preliminary data sug-
gests that human and not murine APC are required to induce
GVHD. Contrary to a previous report, human B lymphocytes do
not appear to contribute to GVHD in the mouse. We found that
SCID mice injected with human PBMC that had been depleted, in
vitro, of activated DC with CMRF-44 antibody survived longer
than undepleted controls (p  0.05). Work is currently under-
way to achieve and assess in vivo depletion of human DC in this
model.
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AN EFFICACY OF INTERFERON- (IFN-) AND INTERLEUKIN-2 (IL-2)
IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES RELAPSE-
PERSISTENCE-PROGRESSION AFTER THE ALLOGENEIC NONMYELOAB-
LATIVE STEM CELL TRANSPLANTATION (NSCT)
Raida, L., Faber, E., Papajik, T., Vlachova, S., Jarosova, M. Hemato-
Oncology Dpt., University Hospital, Olomouc, Czech Republic.
Introduction: GvL reaction belongs to the key mechanisms of
tumour control. Its realisation depends on following circum-
stances: 1) the tumour cells express antigens identiﬁed by donor
T-cells, 2) the engraftment of donor T-cells, 3) the proliferation
activity of tumour and 4) its burden. IFN- and IL-2 belong to the
cytokines allowing to enhance the GvL effect, unfortunately, as
well as the risk of GvHD. We present an experience with the
IFN- and IL-2 administration after allogeneic NSCT in 3 pa-
tients suffering from the different haematological malignancies. 1st
case: 45-years old male with refractory peripheral T-cell lym-
phoma underwent NSCT (ﬂudarabinbusulphanATG) from
MUD. He achieved the complete donor chimerism and the CR of
disease. A prophylactic immunosupression was stopped on day
100 without the development of GvHD. 10 months after NSCT
the skin relapse of lymphoma was proven and the treatment with
cytokines was initiated. IL-2 (3 MIU t.i.w.) has been added after 3
weeks of IFN- (3 MIU t.i.w.) only. At least 25% resolution of skin
involvement was observed 3 months after the start of cytokines
administration. 2nd case: 49-years old male with B-CLL and the
transformation to diffuse large cell lymphoma was allografted
from HLA-identical sibling after conditioning ﬂudarabin and cy-
clophosphamide. He developed the extensive chronic GvHD that
has completely resolved on corticosteroids and CSA and this
immunosuppression was stopped 10 months after NSCT. 11
months after NSCT the patient developed the relapse of dis-
ease with lymph nodes bulk and bone marrow involvement. The
treatment with IFN- was started. 10 doses of 3 MIU applied in
2 months have led to the CR without the need of IL-2 addition.
3rd case: 44-years old male with refractory AML was allografted
from HLA-identical sibling after reduced intensity condition-
ing (ﬂudarabinARA-Cidarubicin). The bone marrow aspirate
evaluation revealed 30% of leukemic blasts on day 14. CSA
was stopped and 5 doses of IFN- (3 MIU) and 3 ones of IL-2 (6
MIU) were administered. The last myelogram evaluation on day
56 proved the reduction of blasts to 11%. Since the start of
cytokines no GvHD has developed in these 3 patients, yet.
Conclusion: The presentation of the 3 cases of different haema-
tological malignancies treated with IFN- and IL-2 but without
any DLI demonstrates the efﬁcacy of this approach that might
become a possible way how to control some malignancies after
NSCT.
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7/ DONOR T CELLS CAUSE LESS GRAFT-VERSUS-HOST DISEASE
WHILE PRESERVING GRAFT-VERSUS-TUMOR ACTIVITY
Waldman, E.D., Alpdogan, O., Petrovic, A., Eng, J.M., Hubbard, V.,
Kochman, A., Muriglan, S., van den Brink, M.R.M. Memorial Sloan-
Kettering Cancer Center, New York, NY.
Recent studies have demonstrated the important role of T cell
homing and its regulation by integrins, chemokine receptors and
ligands in the pathogenesis of acute graft-versus-host disease
(GVHD). Studies by others and by us have suggested that the 47
integrin (LPAM) plays a role in the homing of alloreactive T cells
to the gut and the development of intestinal GVHD. We have
previously demonstrated, using 47 positively and negatively
sorted T cells, that GVHD morbidity and overall mortality are
reduced in hosts receiving 47
 donor T cells. Further analysis
demonstrated reduced T cell inﬁltration of the intestines and less
intestinal GVHD in recipients of 47
 donor T cells, while
inﬁltration other GVHD target organs (skin, thymus) was similar
to that seen in recipients of 47 donor T cells. Concerns
remain however, that, in the setting of allogeneic hematopoietic
stem cell transplantation (HSCT), using a monoclonal antibody
blocking the 4 subunit could interfere with stem cell engraftment.
We hypothesized that blocking only the 7 subunit would also
produce less intestinal GVHD and less overall GVHD morbidity
and mortality, while alleviating concerns regarding stem cell en-
graftment. We used several models with MHC class I and II
disparity, comparing allografts containing donor T cells from ei-
ther wild type mice or from 7
/
 mice. To assess whether
7
/
 T cells have an intact alloreactive response in vivo, we
performed studies with CFSE-labeled donor T cells, which were
transferred into an irradiated allogeneic recipient. We observed no
differences in the fraction of alloreactive T cells or the kinetics of
alloreactive proliferation between recipients of 7
/
 vs. wild
type T cells. Recipients of donor 7
/
 T cells developed less
GVHD morbidity (as determined by clinical GVHD scoring) and
less GVHDmortality than those receiving wild type donor T cells.
In a graft-versus-tumor (GVT) model with P815, we found no
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